With novel selective estrogen receptor degraders (SERDs) expanding treatment options for ER+/HER2- metastatic breast cancer, oncology teams have new opportunities to optimize care for patients with ESR1-mutated disease. In this second episode of a three-part video podcast series, prominent breast oncologists review recent clinical evidence for oral SERDs, including emerging agents and combination strategies. This session features actionable strategies for biomarker-informed patient selection, therapeutic sequencing, and strengthening multidisciplinary collaboration to individualize care. Be sure to download SERD Insights-A Quick Guide to Emerging Data for ESR1-Mutated Breast Cancer to translate the evidence into personalized treatment decision-making in your daily practice.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
99% of listed courses are free
298 of a sample of 300 are free · 416 courses listed here.
Collected from the provider’s public pages
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Operative Anesthesia
- General Pediatrics
- General Surgery
- Geriatric Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Hospital Medicine
- Infectious Disease
- Interventional Cardiology
- Interventional Radiology
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Musculoskeletal Oncology
- Nephrology
- Neurodevelopmental Disabilities
- Neurology
- Neuromuscular Medicine
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pain Medicine
- Patient Education & Health Literacy
- Patient Safety & Quality Improvement
- Pediatric Hematology-Oncology
- Pediatric Neurology
- Practice Management & Ethics
- Pulmonary Disease
- Radiation Oncology
- Regional Anesthesia & Acute Pain
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Urological Oncology
- Urology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pain & Palliative
- Pathology & Lab
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Podcast / audio
- includes On-demand / recorded video
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedMay 8, 2026
-
Last day to claim creditMay 8, 2027 7 months left
-
Med Learning Group The Emerging Role of Oral SERDs in Community Care for Frontline HR+/HER2- Metastatic Breast Cancer
-
Clinical Care Options, LLC (dba Decera Clinical Education) Beyond Resistance: Integrating Next-Generation SERDs Into Community Management of ER-Positive/HER2-Negative Advanced Breast Cancer
-
Physicians’ Education Resource BURST CME(TM) Activity 3: Exploring Combination Strategies in HR+/HER2- MBC: Where Do Oral SERDs Fit In?
-
PRIME Education, Inc. (PRIME®) Ushering in a New Era: Integrating Oral SERDs Into Standard Care for ER-Positive Breast Cancer
-
PRIME Education, Inc. (PRIME®) ESR1 Mastery: From Mutation Monitoring to Targeted Treatment in ER+/HER2- Metastatic Breast Cancer
-
PRIME Education, Inc. (PRIME®) Precision Supportive Care in the Oral SERDs Era: Mitigating and Managing Toxicities
